Sana Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SANA research report →
Range $7 – $12
Price Chart
About the company
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses.
- CEO
- Steven D. Harr
- IPO
- 2021
- Employees
- 142
- HQ
- Seattle, WA, US
Get TickerSpark's AI analysis on SANA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $476.42M
- P/E
- -3.55
- PEG
- -0.06
- P/S
- 0.00
- P/B
- 3.20
- EV/EBITDA
- -4.31
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -97.08%
- ROIC
- -46.41%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-12,750,000+0.0%
- Op Income
- $-190,958,000
- Net Income
- $-244,166,000+8.5%
- EPS
- $-0.96+17.2%
- OCF Growth
- +35.5%
- FCF Growth
- +43.6%
- 52W High
- $5.49
- 52W Low
- $1.56
- 50D MA
- $2.59
- 200D MA
- $3.22
- Beta
- 2.30
- RSI (14)
- 25
- Avg Volume
- 3.28M
No earnings-call transcripts are available for SANA yet.
- Free Float
- 63.8%
- Shares Outstanding
- 299.63M
- Float Shares
- 191.16M
of shares held by institutions
219 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 37.29M | ▼ 135.66K |
| Flagship Pioneering, LLC | 25.00M | 0 |
| Ra Capital Management, L.P. | 18.75M | ▲ 18.75M |
| Blackrock, Inc. | 16.38M | ▼ 290.94K |
| Vanguard Group Inc | 10.46M | ▲ 1.33M |
| Canada Pension Plan Investment Board | 10.22M | ▼ 3.50K |
| State Street Corp | 9.58M | ▼ 1.62M |
| Vanguard Capital Management LLC | 8.61M | ▲ 235.75K |
| Bank Of America Corp | 5.75M | ▲ 2.80M |
| Geode Capital Management, LLC | 4.65M | ▼ 26.97K |
| Marex Group Ltd | 3.99M | ▼ 10.00K |
| Morgan Stanley | 3.02M | ▲ 1.88M |
Held by 205 ETFs
Biggest fund positions in SANA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 5, 26 | Bishop Hans Edgar | other | 8,680 |
| Aug 26, 26 | PATEL DHAVALKUMAR DHIRAJLAL | other | 125,000 |
| Aug 26, 26 | PATEL DHAVALKUMAR DHIRAJLAL | other | 125,000 |
| Aug 27, 26 | PATEL DHAVALKUMAR DHIRAJLAL | other | 41,158 |
| Jul 6, 26 | Bishop Hans Edgar | other | 6,297 |
| Jun 4, 26 | Yang Patrick Y | other | 90,000 |
| Jun 4, 26 | Rosiello Robert L. | other | 90,000 |
| Jun 4, 26 | Seitz Michelle | other | 90,000 |
| Jun 4, 26 | REICIN ALISE | other | 90,000 |
| Jun 4, 26 | Mulligan Richard | other | 90,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SANA coverage
Recent articles, reports, and earnings notes.

Nordicus Partners IPO: What Investors Need to Know
Nordicus Partners Corporation (NASDAQ: NORD) is expected to list on 2026-10-30, but the company has not disclosed a price range yet. The story is less a classic IPO and more a microcap biotech holding-company setup tied to Nordic life sciences assets. Bull case: asset-backed biotech optionality; bear case: no disclosed terms, nominal revenue, and going-concern risk.

Aspen Neuroscience IPO Preview: Parkinson’s Cell Therapy Meets Execution Risk
Aspen Neuroscience is expected to list on Nasdaq under the symbol ASPE on 2026-10-30, but the price range was not disclosed before pricing. The company is a clinical-stage Parkinson’s disease biotech, so the bull case is a large unmet-need market and the bear case is heavy clinical and regulatory risk.
Want a deeper read on SANA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Bears are Losing Control Over Sana (SANA), Here's Why It's a 'Buy' Now
zacks.com · Nov 16
2 healthcare stocks to turn $10 into $100 by next year
finbold.com · Nov 11
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
globenewswire.com · Nov 5
Sana Biotechnology: A Shot At Diabetes
seekingalpha.com · Oct 13
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 14
Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com · Sep 10
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
seekingalpha.com · Sep 10
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com · Sep 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.